Naturally occurring polyamine fact sheet
Spermidine
Also known as dietary spermidine, polyamine
Spermidine occurs in foods and cells and is connected to autophagy in laboratory research. The largest cognitive trial did not show a significant memory benefit over placebo.
Quick answer
Spermidine is a real cellular metabolite and a plausible autophagy research target, but it is not an FDA-approved drug for cognitive decline or aging. A 12-month randomized trial in older adults did not improve its primary memory outcome.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Spermidine?
Spermidine is a polyamine involved in cell growth, protein function, and cellular maintenance. It occurs in human cells and in foods.
Laboratory and animal findings connect spermidine with autophagy and lifespan biology, but those findings do not establish a human anti-aging effect.
Why are people interested in it?
Autophagy is a core cellular recycling process, and dietary observational studies have linked higher spermidine intake with some favorable outcomes.
Observational diet patterns can carry many confounders, so randomized trials are essential.
Current regulatory status
Spermidine is not an FDA-approved drug for memory, cognitive decline, dementia prevention, autophagy enhancement, or aging. Dietary supplements are not preapproved by FDA for effectiveness.
What is it approved for?
No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
What is it being studied for?
Evidence snapshot
Human observational evidence and small trials generated interest, but the phase 2b SmartAge trial did not show a significant benefit on its primary memory endpoint after 12 months.
Potential benefits being researched
- A small pilot generated a possible memory signal that justified a larger trial.
- The larger SmartAge trial did not confirm a significant improvement in the primary memory outcome, although exploratory biomarker work continues.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- The studied food-extract formulation was generally tolerated, but available trials are not large enough for uncommon harms.
- A supplement extract is not interchangeable with dietary intake or endogenous spermidine biology.
- Commercial product composition and labeling may vary.
What we still do not know
- Whether another population or outcome would show a reproducible benefit
- Whether supplement exposure meaningfully changes autophagy in relevant human tissues
- Long-term safety and interaction effects
- Whether observational diet associations are causal
Plain-English takeaway
Spermidine is mechanistically interesting, but the best cognitive trial so far was negative on its primary outcome. That is a reason for better research, not a benefit claim.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1SmartAge randomized clinical trial
Phase 2b trial reporting no significant improvement in its primary memory endpoint.
- 2SmartAge trial protocol
Prospective protocol defining the trial design and planned cognitive outcomes.
- 3Mechanisms of spermidine-related autophagy research
Peer-reviewed mechanistic review that helps separate biological rationale from clinical proof.
- 4FDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.